Brind.

Royalty Pharma outperformed the market so far this year, based on data from August 6, 2025.

1 report, 1 independent Updated Aug 6

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Royalty Pharma

How it developed

Newest first. Tap a step to see who reported it.

Sep 5Novartis' trial results are impacting Royalty Pharma's investment decisions.Sub-event
Aug 6Royalty Pharma outperformed the market so far this year.1 source
- Zacks

Keep exploring

The entities involved

Royalty Pharma
biopharmaceutical company based in New York City
- Visteon filed transaction details with the SEC and traded on the Nasdaq stock exchange on June 6, 2026.Sun 17:49
- Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.Sun 02:34

Related events

Pablo Legorreta was named the founder and CEO of Royalty Pharma, which provides funding in exchange for royalty rights.Jun 7

Coverage

Newest first; wire copies grouped

Aug 6ZacksRoyalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates Royalty Pharma (RPRX) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.1 per share. This co